Water-based cannabinoid and opioid compositions
Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.
1. A method of treating a disease in a human suffering from the disease wherein the disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, multiple sclerosis, dementia, and epilepsy, the method consisting essentially of administering to the human in need thereof a cannabinoid bound to a protein selected from the group consisting of: albumin, α globulin, β globulin, and γ globulin to effectively treat the disease in the human in need thereof.
2. The method according to claim 1 , wherein the cannabinoid bound to the protein is in a pharmaceutical composition in the form of a tablet, capsule, lozenge, wafer, sachet, patch, ampoule, vial, metered-dose inhaler or pre-filled syringe.
3. The method according to claim 2 , wherein the pharmaceutical composition is in the form of a tablet or capsule.
4. The method according to claim 1 , wherein the cannabinoid is selected from the group consisting of: Δ9-THC, Δ8-THC, tetrahydrocannabinoic acid (THCA), CBD, cannabidiolic acid (CBDA), cannabinol (CBN), cannabigerol (CBG), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA) and cannabichromene (CBC).
5. The method according to claim 4 , wherein the cannabinoid is Δ9-THC.
6. The method according to claim 4 , wherein the cannabinoid is CBD.
7. The method according to claim 2 , wherein the amount of cannabinoid in the pharmaceutical composition is between 1 mg and 1 g.
8. The method according to claim 1 , wherein the ratio of protein to cannabinoid is between 100:1 and 1:1 according to a weight/weight basis.
9. The method according to claim 8 , wherein the ratio of protein to cannabinoid is between 20:1 and 1:1 according to a weight/weight basis.
10. The method according to claim 1 , wherein the protein is albumin.
11. The method according to claim 10 , wherein the albumin is selected from the group consisting of recombinant human albumin, human serum albumin, bovine serum albumin and egg albumin (ovalbumin).
12. The method according to claim 2 , wherein the amount of protein-bound cannabinoid is between 0.1% and 95% of the pharmaceutical composition.
13. The method according to claim 12 , wherein the amount of protein-bound cannabinoid is between 1% and 70% of the pharmaceutical composition.
14. The method according to claim 2 , wherein the pharmaceutical composition comprises less than 10% by weight non-protein-bound cannabinoid.